4(3H)-Quinazolinone, 7-(cyclopropylmethoxy)-5-fluoro-2-[[(trans-4-hydroxycyclohexyl)thio]methyl]- manufacturers
- RBN012759
-
- $107.00 / 1mg
-
2025-11-10
- CAS:2360851-29-0
- Min. Order:
- Purity: 99.96%
- Supply Ability: 10g
|
| | 4(3H)-Quinazolinone, 7-(cyclopropylmethoxy)-5-fluoro-2-[[(trans-4-hydroxycyclohexyl)thio]methyl]- Basic information |
| Product Name: | 4(3H)-Quinazolinone, 7-(cyclopropylmethoxy)-5-fluoro-2-[[(trans-4-hydroxycyclohexyl)thio]methyl]- | | Synonyms: | 4(3H)-Quinazolinone, 7-(cyclopropylmethoxy)-5-fluoro-2-[[(trans-4-hydroxycyclohexyl)thio]methyl]-;RBN012759;poly ADP ribose polymerase,pro-tumor,cancer,PARP14,PARP,RBN012759,macrophage,RBN 012759,Inhibitor,inflammatory,inhibit,RBN-012759;7-(Cyclopropylmethoxy)-5-fluoro-2-(((trans-4-hydroxycyclohexyl)thio)methyl)quinazolin-4(1H)-one;RBN012759, 10 mM in DMSO | | CAS: | 2360851-29-0 | | MF: | C19H23FN2O3S | | MW: | 378.46 | | EINECS: | | | Product Categories: | | | Mol File: | 2360851-29-0.mol | ![4(3H)-Quinazolinone, 7-(cyclopropylmethoxy)-5-fluoro-2-[[(trans-4-hydroxycyclohexyl)thio]methyl]- Structure](CAS/20200611/GIF/2360851-29-0.gif) |
| | 4(3H)-Quinazolinone, 7-(cyclopropylmethoxy)-5-fluoro-2-[[(trans-4-hydroxycyclohexyl)thio]methyl]- Chemical Properties |
| storage temp. | 4°C, protect from light | | solubility | DMSO : 250 mg/mL (660.57 mM; Need ultrasonic) | | form | A solid | | color | White to off-white | | InChI | InChI=1S/C19H23FN2O3S/c20-15-7-13(25-9-11-1-2-11)8-16-18(15)19(24)22-17(21-16)10-26-14-5-3-12(23)4-6-14/h7-8,11-12,14,23H,1-6,9-10H2,(H,21,22,24)/t12-,14- | | InChIKey | NKZDEFKPZSLQRF-MQMHXKEQSA-N | | SMILES | N1C2=C(C(F)=CC(OCC3CC3)=C2)C(=O)NC=1CS[C@@H]1CC[C@@H](O)CC1 |
| | 4(3H)-Quinazolinone, 7-(cyclopropylmethoxy)-5-fluoro-2-[[(trans-4-hydroxycyclohexyl)thio]methyl]- Usage And Synthesis |
| Uses | RBN012759 is an inhibitor of PARP14, which is useful in the treatment of cancer and inflammatory diseases. | | in vivo | RBN012759 (500 mg/kg BID; p.o.) is well-tolerated in mice with repeat dosing[1]. ?
RBN012759 (100 mg/kg; p.o.) exhibits moderate orally bioavailability (30%) and short plasma half-life (0.4 h) due to moderate clearance (54 mL/min/kg) and low steady-state volume of distribution (1.4 L/kg) in mice[1]. | | IC 50 | PARP14: <3 nM (IC50); PARP4: 10 μM (IC50); PARP5a: 8 μM (IC50); PARP5b: 10 μM (IC50); PARP6: 4 μM (IC50); PARP7: 4 μM (IC50); PARP8: 20 μM (IC50); PARP10: 1 μM (IC50); PARP11: 1 μM (IC50); PARP12: 5 μM (IC50); PARP15: 3 μM (IC50); PARP16: 6 μM (IC50) |
| | 4(3H)-Quinazolinone, 7-(cyclopropylmethoxy)-5-fluoro-2-[[(trans-4-hydroxycyclohexyl)thio]methyl]- Preparation Products And Raw materials |
|